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With the creation of the Somatic Symptom and Related Disorders category of the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition in 2013, the functional neurological (symptom) disorder diagnostic criteria underwent transformative
changes. These included an emphasis on ‘rule-in’ physical examination signs/semiological features guiding diagnosis and the re-
moval of a required proximal psychological stressor to be linked to symptoms. In addition, the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition somatization disorder, somatoform pain disorder and undifferentiated somatoform disorder
conditions were eliminated and collapsed into the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition somatic
symptom disorder diagnosis. With somatic symptom disorder, emphasis was placed on a cognitive-behavioural (psychological)
formulation as the basis for diagnosis in individuals reporting distressing bodily symptoms such as pain and/or fatigue; the need
for bodily symptoms to be ‘medically unexplained’ was removed, and the overall utility of this diagnostic criteria remains debated.
A consequence of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition restructuring is that the diagnosis of
somatization disorder that encompassed individuals with functional neurological (sensorimotor) symptoms and prominent other
bodily symptoms, including pain, was eliminated. This change negatively impacts clinical and research efforts because many
patients with functional neurological disorder experience pain, supporting that the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition would benefit from an integrated diagnosis at this intersection. We seek to revisit this with modifications,
particularly since pain (and a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition somatization disorder comor-
bidity, more specifically) is associated with poor clinical prognosis in functional neurological disorder. As a first step, we systemat-
ically reviewed the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition somatization disorder literature to detail
epidemiologic, healthcare utilization, demographic, diagnostic, medical and psychiatric comorbidity, psychosocial, neurobiological
and treatment data. Thereafter, we propose a preliminary revision to the Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition allowing for the specifier functional neurological disorder ‘with prominent pain’. To meet this criterion, core function-
al neurological symptoms (e.g. limb weakness, gait difficulties, seizures, non-dermatomal sensory loss and/or blindness) would
have ‘rule-in’ signs and pain (>6 months) impairing social and/or occupational functioning would also be present. Two optional
secondary specifiers assist in characterizing individuals with cognitive-behavioural (psychological) features recognized to amplify or
perpetuate pain and documenting if there is a pain-related comorbidity. The specifier of ‘with prominent pain’ is etiologically neu-
tral, while secondary specifiers provide additional clarification. We advocate for a similar approach to contextualize fatigue and
mixed somatic symptoms in functional neurological disorder. While this preliminary proposal requires prospective data and add-
itional discussion, these revisions offer the potential benefit to readily identify important functional neurological disorder sub-
groups—resulting in diagnostic, treatment and pathophysiology implications.
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Introduction
Pierre Briquet, the French physician and psychologist,
published his Treatise on Hysteria in 1859 on 430
patients that provided the basis for the modern-day
somatization disorder (SD) (Briquet syndrome) diagnosis
(see Fig. 1) (Briquet, 1859; Mai and Merskey, 1980,
1981). Briquet wrote that hysteria was a ‘neurosis of the
brain in which the observed phenomena consist chiefly of
a perturbation of vital activities, which serve as the mani-
festation of affective feeling’. While sensorimotor func-
tional neurological symptoms were part of the original
symptom complex, pain was a core symptom. Briquet
wrote, ‘there is not a single woman with this neurosis
Graphical Abstract
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who does not have some muscle pain during the course
of the illness’ (Briquet, 1859). In the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) Somatization disorder (DSM-IV-SD) category,
the presence of at least one functional neurological symp-
tom occurring at some point during the illness course
was required—along with four pain symptoms, two
gastrointestinal symptoms and one sexual
symptom(American Psychiatric Association, 2000). While
the DSM-IV-SD criteria were criticized for its somewhat
arbitrary symptom domain requirements(Mayou et al.,
2005; Rief et al., 2011), a strength was having one diag-
nosis encompass the frequently encountered intersection
of functional neurological disorder (FND) with prominent
pain.
With Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5), the ‘Somatic Symptom
and Related Disorders’ section underwent major changes
(American Psychiatric Association, 2013; Dimsdale et al.,
2013). The DSM-IV-SD, somatoform pain disorder and un-
differentiated somatoform disorder diagnoses were re-con-
ceptualized into one condition—somatic symptom disorder
(SSD). The SSD diagnostic criteria removed the need for
physical symptoms to be ‘medically unexplained’, and in-
stead emphasized a cognitive-behavioural (psychological)
formulation whereby individuals were deemed to engage
with bodily symptoms (>6 months duration) using
unhelpful thought patterns, behavioural strategies and/or
emotional responses. Hypochondriasis was reframed as ill-
ness anxiety disorder, and conversion disorder was re-con-
ceptualized as FND. Major changes to the FND diagnostic
criteria included an emphasis on positive neurological
examination signs ‘ruling-in’ diagnosis, as well as the re-
moval of the need to relate a proximal stressor to symp-
tom onset; the requirement to exclude feigning, a
diagnostic challenge relevant only to a minority of cases,
was also eliminated(Stone et al., 2010a). Notably, the
DSM-5 FND diagnostic category focuses on motor symp-
toms (e.g. limb weakness, abnormal movements, seizures)
and sensory deficits (e.g. non-dermatomal sensory loss,
blindness). As such, a single diagnosis encompassing
patients with FND and prominent pain is now no longer
present in the DSM-5 framework, requiring clinicians to
consider dual FND and SSD diagnoses. This is problematic
given that the psychological diagnostic criteria for SSD and
its potential application to individuals with known symp-
tom-related medical problems have been met with mixed
reviews (van der Feltz-Cornelis et al., 2018; Lehmann
et al., 2019; Burton et al., 2020; Scamvougeras and
Howard, 2020), resulting in variable use of the SSD diag-
nosis amongst FND experts (Aybek et al., 2020).
In FND, pain is common and clinically relevant (Glass
et al., 2018). For example, in a large cohort (n¼ 107) of
patients with functional limb weakness, pain beyond the
Figure 1 Depicts Pierre Briquet (1796–1881; left panel) alongside his Treatise on Hysteria book published in 1859 (right panel).
Left panel image reproduced with permission from Fontoura P. The ‘Ajuda Paralyses’: history of a neuropsychiatric debate in mid-19th-century
Portugal. Brain 2010; 133: 3141–52. Right panel image is in the public domain. Source: Bibliothèque nationale de France, département Sciences et
techniques.
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affected limb (64%), headache (40%) and back pain
(38%) were frequently present and differentiated FND
from neurological controls (Stone et al., 2010b). In 160
functional movement disorder patients, one-fourth
reported pain with functional motor symptom onset
(Gelauff et al., 2020). Robust associations have also been
described between functional dystonia and complex re-
gional pain syndrome (Popkirov et al., 2019). Notably,
the presence of chronic pain differentiates individuals
with functional (psychogenic non-epileptic/dissociative)
seizures from those with epilepsy (Gazzola et al., 2012).
In pediatric FND, pain is especially common, with one
study in 194 children reporting that 56% had concurrent
pain (Kozlowska et al., 2007). Reduced quality of life
and poor clinical outcomes have been linked to pain in
FND (Ibrahim et al., 2009; Myers et al., 2012). In add-
ition, FND patients with predominantly pain-related med-
ical disability have been excluded from physiotherapy
clinical trials, highlighting that this subgroup is being
identified indirectly as a distinct entity (Nielsen et al.,
2017). Relatedly, pathophysiological models of FND
emphasizing altered predictive processing, multimodal in-
tegration and emotion processing fit well with a close
intersection between sensorimotor FND and pain
(Edwards et al., 2012; Diez et al., 2019; Pick et al.,
2019), further supporting the need to better characterize
the FND—pain intersection.
In this article, we first revisit the explicit intersection of
FND and pain in the DSM-IV-SD diagnosis by perform-
ing a systematic review of the DSM-IV-SD literature to
detail relevant epidemiologic, healthcare utilization, demo-
graphic, diagnostic, medical and psychiatric comorbidity,
psychosocial, neurobiological and treatment data.
Thereafter, we subsequently propose a preliminary revi-
sion to the DSM-5 FND diagnostic criteria that allows
for the etiologically neutral specifier of FND ‘with prom-
inent pain’ (akin to a FND plus syndrome). This import-
ant distinction will greatly aid cohort characterization
across diagnostic, treatment and pathophysiology studies,
including providing increased clarity regarding the types
of patients enrolled in clinical and translational research
studies.
Materials and methods
Search strategy
This study was registered in PROSPERO
(CRD42020159179). We searched PubMed, PsycINFO
and Embase with the terms ‘somatization disorder’ OR
‘Briquet’ from inception to 30 June 2019 in accord with
PRISMA guidelines. Reference lists from identified origin-
al research articles and reviews were also scrutinized to
identify articles meeting eligibility criteria.
Eligibility criteria
Original research studies with patients meeting DSM-IV
criteria for SD were included. Only articles in which the
DSM-IV-SD diagnosis was obtained by interview (struc-
tured or unstructured), as opposed to symptom checklist
or self-report questionnaire, were included (Carson et al.,
2015). We identified within and between-group studies in
the following content areas: epidemiology, healthcare util-
ization, diagnosis, medical and psychiatric/psychological
comorbidities, predisposing vulnerabilities, neural mecha-
nisms, treatment and prognosis. Case reports or series
(n< 10), review articles, those not written in English, and
content published only in abstract or dissertation form
were excluded. Articles not using DSM-IV-SD diagnostic
criteria [e.g. abridged SD, Diagnostic and Statistical
Manual of Mental Disorders, Third Edition, International
Classification of Diseases, Tenth Edition or Perley &
Guze criteria (Perley and Guze, 1962)] were also
excluded (see Table 1). The rationale for this exclusion
criterion is that only DSM-IV-SD diagnostic criteria expli-
citly required at least one functional neurological symp-
tom. Structural neuroimaging studies of DSM-IV-SD were
also omitted given that they were previously reviewed
elsewhere (Begue et al., 2019).
Data extraction
EndNote was used to compile abstracts from search
results of all three databases. After removing duplicates,
J.M. and P.R.A. independently applied inclusion/exclusion
criteria to determine articles to be read. Discrepancies be-
tween the two reviewers were independently resolved by
D.L.P. From the list of articles selected, J.M. and P.R.A.
narrowed down studies based on inclusion/exclusion crite-
ria. Included articles were evaluated for quality using the
National Institutes of Health Study Quality Assessment
Tools guidelines (National Institutes of Health: National
Heart Lung and Blood Institute) (see Supplementary
Table 1). See Fig. 2 for a PRISMA flow diagram of the
systematic review (Moher et al., 2009).
Results
Epidemiology
The prevalence of DSM-IV-SD was recorded in eight
studies (Escobar et al., 1998; Lynch et al., 1999; Simon
and Gureje, 1999; Fink et al., 2004, 2005; Smith et al.,
2005; Prerana et al., 2017; Chander et al., 2019). The
largest study (n¼ 5447) performed in 14 countries, deter-
mined that DSM-IV-SD had a prevalence of 1.4% among
primary care outpatients (Simon and Gureje, 1999). Two
studies performed in psychiatry clinics, found that 2.6–
6.7% met criteria for DSM-IV-SD (Prerana et al., 2017;
Chander et al., 2019). Among first time neurology
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referrals (n¼ 120), 7% in one cohort were diagnosed
with DSM-IV-SD (Fink et al., 2005).
Healthcare utilization
Five studies investigated healthcare utilization in DSM-IV-
SD patients, although none had an isolated DSM-IV-SD
cohort (Lynch et al., 1999; Hiller et al., 2003; Smith
et al., 2005; Frostholm et al., 2014; Weiss et al., 2017),
and two studies had very limited inclusion of DSM-IV-
SD patients and will not be further discussed (Lynch
et al., 1999; Smith et al., 2005). Weiss et al examined
254 patients (55 with DSM-IV-SD) across 7 outpatient
psychotherapy clinics, identifying that those with DSM-
IV-SD had a higher number of outpatient doctor visits
(an average of 36.5 outpatient doctor visits in the prior
year) compared to those with undifferentiated somato-
form disorder, somatoform pain disorder and severe
DSM-5 SSD (x ¼ 25.9, 24.7 and 32.5 outpatient doctor
visits, respectively) (Weiss et al., 2017). The somatoform
disorder cohort (including those with DSM-IV-SD)
showed two times higher outpatient healthcare utilization
compared to the general German population. Negative ill-
ness perceptions in 144 patients with somatoform disor-
ders (26 with DSM-IV-SD) correlated with greater
healthcare expenditures (Frostholm et al., 2014). In 172
subjects (54 with DSM-IV-SD) enrolled in an inpatient
cognitive behavioural therapy (CBT) treatment pro-
gramme for somatic symptoms, individuals with DSM-IV-
SD had higher outpatient costs than those with abridged
SD, and the entire cohort had 2.5% higher outpatient
costs compared to average German healthcare system
costs (Hiller et al., 2003).
Demographics
Seven studies investigated demographic characteristics in
DSM-IV-SD cohorts (n> 50) (Guz et al., 2004; Allen
Table 1 The historical evolution of Briquet syndrome diagnostic criteria
Diagnostic
criteria
Name(s) Date first
described
Number of symp-
toms required
Number of symptom
groups required
Neurologic
symptoms
Age of onset
requirement
Briquet Briquet Syndrome
or Hysteria
1859 25 9 of 10a Not required Onset of symp-
toms by 30
Robins and
O’Neal
Hysteria 1953 18 7 of 10a Not required More than one
major oper-
ation or two
hospitalizations
by 21
Perley and Guze Hysteria 1962 15 9 of 10a Not required Significant medical
history by 35
Feighner Hysteria 1967 Definite diagnosis:
25
Probable diagnosis:
20–24
9 of 10a Not required Chronic or recur-
rent illness by
30
ICD-9 Hysteria
unspecified
1977 Not specified Not specified Not specified Not specified
DSM-III SD 1980 Women: 14
Men: 12
Not required Not required Onset of symp-
toms by 30
DSM-III-R SD 1987 13 Not required Not required Onset of symp-
toms by 30
Abridged Escobar
or Somatic
Symptom Index
SD 1987 Women: 6
Men: 4
Not required Not required Not specified
ICD-10 SD 1990 Not specified Not specified Not required 2-year duration of
unexplained
somatic symp-
toms needed
DSM-IV SD 1994 8 4b Required Onset of symp-
toms by 30
DSM-5 SSD 2013 1 Not specified Not required >6 months of
symptoms
duration
aGroup 1: Feeling sickly for most of life, or headache; Group 2: blindness, paralysis, anaesthesia, aphonia, fits or convulsions, unconsciousness, amnesia, deafness, hallucinations or
urinary retention; Group 3: fatigue, lump in the throat, fainting spells, visual blurring, weakness or dysuria; Group 4: breathing difficulty, palpitation, anxiety attacks, chest pain or diz-
ziness; Group 5: anorexia, weight loss, marked fluctuations in weight, nausea, abdominal bloating, food intolerances, diarrhea or constipation; Group 6: abdominal pain or vomiting;
Group 7: dysmenorrhea, menstrual irregularity, including amenorrhea for at least 2 months, or excessive menstrual bleeding; Group 8: sexual indifference, sexual frigidity, dyspar-
eunia, other sexual difficulties or vomiting for all 9 months of pregnancy; Group 9: back pain, joint pain, extremity pain, burning pains of the sexual organs, mouth or rectum or other
bodily pains; Group 10: nervousness, fears, depressed feelings, need to quit working or inability to carry on regular duties because of feeling sick, crying easily, feeling life was hope-
less, thinking a good deal about dying, wanting to die, thinking of suicide or suicide attempts.
bGroup 1: pain symptoms; Group 2: gastrointestinal symptoms; Group 3: functional neurological symptoms; Group 4: sexual symptoms.
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et al., 2006; Garcia-Campayo et al., 2007; Kuwabara
et al., 2007; Manchikanti et al., 2007; Fjorback et al.,
2013; Prerana et al., 2017). DSM-IV-SD had a female
predominance (75–89%), with an age range typically be-
tween 20 and 50 years old (Guz et al., 2004; Allen et al.,
2006; Garcia-Campayo et al., 2007; Kuwabara et al.,
2007; Manchikanti et al., 2007; Fjorback et al., 2013;
Prerana et al., 2017). Educational background reflected
regional differences; 22 6 8.4 years of schooling were
reported in a Japanese cohort (Kuwabara et al., 2007),
while only 14% of participants in a Turkish DSM-IV-SD
study completed college (Guz et al., 2004). Rates of un-
employment were reported in 4 of 7 studies and ranged
from 5% to 45% (Guz et al., 2004; Allen et al., 2006;
Fjorback et al., 2013; Prerana et al., 2017). Patients
receiving disability ranged from 19% to 53% (Allen
et al., 2006; Garcia-Campayo et al., 2007; Fjorback
et al., 2013). The majority of patients were married (Guz
et al., 2004; Allen et al., 2006; Garcia-Campayo et al.,
2007; Fjorback et al., 2013; Prerana et al., 2017).
Diagnostic criteria
Four studies evaluated the stability or specificity of the
DSM-IV-SD diagnostic criteria (Lynch et al., 1999; Simon
and Gureje, 1999; Fink et al., 2005; Smith et al., 2005).
A random sample of 3196 primary care patients from
the World Health Organization Psychological Problems in
General Health Care study conducted in 15 sites across
14 countries were assessed regarding the stability of a
lifetime DSM-IV-SD diagnosis (Simon and Gureje, 1999).
Of the 74 (2.3% of total sample) patients initially meet-
ing lifetime DSM-IV-SD criteria, only 21 (28%) of those
same individuals in a subsequent interview 1 year later
again endorsed a history of DSM-IV-SD. This suggests
that the DSM-IV-SD diagnosis was subject to recall bias
(an issue not necessarily specific to the DSM-IV-SD diag-
nosis). Compared to other multiple somatic symptom
classification systems, the DSM-IV-SD diagnostic criteria
were the most narrowly defined and restrictive (Lynch
et al., 1999; Fink et al., 2005; Smith et al., 2005). For
example, in 119 patients attending a primary care centre,
only 1 (0.84%) met DSM-IV-SD criteria; 10 (8%) met
SD when only one gastrointestinal symptom was required
and sexual/reproductive symptoms were excluded (Lynch
et al., 1999). Similarly, the DSM-IV-SD prevalence was
1% versus 7% by International Classification of Diseases,
Tenth Edition in a sample of 198 patients with medically
unexplained symptoms (Fink et al., 2005); in 206 pri-
mary care patients with medically unexplained symptoms,
only 3 (1.5%) met DSM-IV-SD criteria while 39 (19%)
met the abridged Escobar criteria (Smith et al., 2005).
Medical comorbidities—functional
somatic disorders
Eight studies evaluated the intersection of DSM-IV-SD
and medical comorbidities (Hiller et al., 2000; Miller
et al., 2001; North et al., 2004; Schrag et al., 2004;
Figure 2 PRISMA flow diagram of the systematic review of somatization disorder, as defined using DSM-IV diagnostic criteria.
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Manchikanti et al., 2007, 2008; Padhy et al., 2016;
Chander et al., 2019). The intersection of DSM-IV-SD
and functional somatic disorders were primarily investi-
gated in two distinct groups, patients with irritable bowel
syndrome (IBS) and individuals with chronic pain disor-
ders (Hiller et al., 2000; Miller et al., 2001; North et al.,
2004; Manchikanti et al., 2007, 2008; Padhy et al.,
2016). Three studies were conducted in IBS cohorts
(n¼ 24–56), two from outpatient gastroenterology (Miller
et al., 2001; North et al., 2004). The prevalence of
DSM-IV-SD in those with IBS ranged from 16% to 25%
(Miller et al., 2001; North et al., 2004; Padhy et al.,
2016). In these studies, patients with IBS with comorbid
DSM-IV-SD showed increased abnormal illness behav-
iours, greater psychiatric comorbidities and higher rates
of other functional somatic disorders compared to indi-
viduals with IBS alone (Miller et al., 2001; North et al.,
2004; Padhy et al., 2016). Three studies looked at the
intersection of chronic pain and DSM-IV-SD (Hiller
et al., 2000; North et al., 2004; Manchikanti et al.,
2007). Ten of 60 individuals attending an inpatient
chronic pain programme had DSM-IV-SD and were
grouped together with 31 total patients framed as ‘other
functional somatic disorders’ (Hiller et al., 2000). The
chronic pain group with a comorbid other functional
somatic disorder displayed a greater number of bodily
symptoms and pain symptoms, but similar psychological
pain distress profiles, depression and anxiety as the
chronic pain only group. In a separate outpatient cohort
of 500 patients taking opioids for chronic pain, 30% had
comorbid DSM-IV-SD (Manchikanti et al., 2007). Higher
rates of current illicit drug use were also observed in men
with SD versus without (22% versus 9%) (Manchikanti
et al., 2007). In 438 patients with chronic spinal pain, a
DSM-IV-SD diagnosis (n¼ 162) did not significantly in-
fluence false positive (placebo) rates following a single
anesthetic administration (Manchikanti et al., 2008).
While not well studied, in addition to functional somatic
disorders, patients with DSM-IV-SD were also reported
to have cardiovascular and endocrine conditions, and per-
ipheral injuries (including fractures) as common comorbid
medical conditions (Schrag et al., 2004; Chander et al.,
2019).
Psychiatric comorbidities
Eleven studies characterized psychiatric comorbidities in
DSM-IV-SD (Battaglia et al., 1998; Rief et al., 2001;
Carey et al., 2003; Mohlman et al., 2004; Brown et al.,
2005; Garcia-Campayo et al., 2007; Ozturk and Sar,
2008; Sertoz et al., 2009; Spitzer et al., 2009; Taycan
et al., 2014; Chander et al., 2019). Many studies
reported high rates of mood disorders (10–90%) (Brown
et al., 2005; Sertoz et al., 2009; Taycan et al., 2014;
Chander et al., 2019); panic attacks (41%) (Brown et al.,
2005); lifetime post-traumatic stress disorder (PTSD) or
complex PTSD (14–55%) (Brown et al., 2005; Spitzer
et al., 2009; Taycan et al., 2014); generalized anxiety dis-
order (45%) (Brown et al., 2005); any anxiety disorder
(15%) (Chander et al., 2019); lifetime dissociative dis-
order (28–50%) (Brown et al., 2005; Taycan et al.,
2014) and borderline personality disorder (15%) (Taycan
et al., 2014) within DSM-IV-SD cohorts. Similarly, DSM-
IV-SD was found to be highly comorbid within PTSD
(35%), panic disorder (11%) and dissociative disorder
(33%) populations (Carey et al., 2003; Mohlman et al.,
2004; Ozturk and Sar, 2008).
The largest sample of DSM-IV-SD patients (n¼ 70)
reported that 39% of patients did not have another
DSM-IV Axis I comorbidity (Garcia-Campayo et al.,
2007). The remaining DSM-IV-SD population had
comorbid mood disorders [major depressive disorder
(MDD) 13%; dysthymia 11%], anxiety disorders (panic
disorder 13%; generalized anxiety disorder 10%; agora-
phobia 4%), or another mood/anxiety disorder (6%).
Sixty-four percent of individuals with DSM-IV-SD also
met criteria for one or more personality disorders
(Garcia-Campayo et al., 2007).
Several studies also examined relationships between
psychiatric comorbidities and dimensional psychological
characteristics in DSM-IV-SD. One study used the Brief
Symptom Inventory to assess differences in psychopath-
ology between DSM-IV-SD with complex PTSD (n¼ 10),
DSM-IV-SD without complex PTSD (n¼ 18) and MDD
without complex PTSD (n¼ 27) (Spitzer et al., 2009).
Here, patients with DSM-IV-SD and complex PTSD
exhibited higher psychoticism and interpersonal problems
than both other groups, and higher obsessive compulsive
and anger–hostility tendencies than the DSM-IV-SD with-
out complex PTSD group. Both DSM-IV-SD groups
showed greater obsessionality, anxiety, anger–hostility
and global severity of psychopathology compared to the
MDD group (Spitzer et al., 2009). Furthermore, another
study reported that the co-occurrence of major depression
and somatization (37.5% with full-criteria DSM-IV-SD)
was linked to increased psychopathology on the
Symptom Checklist-90 Revised (Rief et al., 2001). In an-
other study, 18 DSM-IV-SD patients with comorbid panic
disorder showed higher novelty seeking scores compared
to 41 individuals with panic disorder and 22 healthy con-
trols (HCs), and novelty seeking positively correlated
with number of somatic symptoms (Battaglia et al.,
1998).
DSM-IV-SD versus Other DSM-IV
somatoform disorders
Five studies compared DSM-IV-SD to other somatoform
disorders (Escobar et al., 1998; Sanyal et al., 1998; Guz
et al., 2004; Espirito-Santo and Pio-Abreu, 2009;
Kırpınar et al., 2016), including two examining similar-
ities and differences between DSM-IV-SD and hypochon-
driasis (Escobar et al., 1998; Kırpınar et al., 2016) and
three comparing DSM-IV-SD and DSM-IV conversion
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disorder (Sanyal et al., 1998; Guz et al., 2004; Espirito-
Santo and Pio-Abreu, 2009). In a primary care setting of
1456 outpatients, 49 patients with hypochondriasis and
20 with DSM-IV-SD were identified (Escobar et al.,
1998). One in five patients with DSM-IV-SD also had
hypochondriasis; a higher rate of DSM-IV-SD amongst
hypochondriasis patients was also observed with a preva-
lence of 9% versus 1% in those without hypochondriasis.
Kırpınar et al. characterized a consecutive sample of 73
outpatients in a somatoform disorders unit ([DSM-IV-SD
(n¼ 51) and hypochondriasis (n¼ 22)], identifying a
higher female prevalence in the DSM-IV-SD group (71%
versus 41%) and higher heath anxiety in the hypochon-
driasis group (Kırpınar et al., 2016). The two cohorts
showed similar Beck Anxiety Inventory, Hamilton
Depression Rating Scale, Somatosensory Amplification
Scale, Somatoform Dissociation Questionnaire,
Dissociative Experiences Scale and State-Trait Anxiety
Inventory scores.
DSM-IV-SD (n¼ 40), conversion disorder (n¼ 26) and
dissociative disorders (n¼ 38) were compared in one
study (Espirito-Santo and Pio-Abreu, 2009), with more
commonalities found amongst the dissociative and con-
version disorder groups (e.g. greater dissociation) than
between the DSM-IV-SD and conversion disorder groups.
More depression and paranoia symptoms were seen in
those with dissociative disorders, while more somatic and
obsessive symptoms were appreciated in the DSM-IV-SD
group. In a separate study, 71 DSM-IV-SD patients had
lower paranoia and psychotic personality traits compared
to 87 individuals with DSM-IV conversion disorder (Guz
et al., 2004). Individuals with DSM-IV-SD also exhibited
lower self-appraisal compared to both patients with con-
version disorder and HCs (Sanyal et al., 1998).
Comorbid DSM-IV-SD in FND
Six studies reported on the co-occurrence of DSM-IV-SD
and FND (Interian et al., 2004; Schrag et al., 2004;
Marchetti et al., 2008; Stone et al., 2010b; Epstein et al.,
2016; Gelauff et al., 2019). In one study, 8 (12.5%) of
36 patients with functional movement disorder met crite-
ria for comorbid SD (Epstein et al., 2016); 12 (32%) of
38 patients with probable or diagnosed functional dys-
tonia had comorbid DSM-IV-SD in another study (Schrag
et al., 2004). Likewise, 19% of patients experiencing
functional (non-epileptic/dissociative) seizures (n¼ 27)
also had DSM-IV-SD (Marchetti et al., 2008). In a large
sample of 107 patients with functional limb weakness,
27% had a comorbid DSM-IV-SD (Stone et al., 2010b).
However, the presence of functional neurological symp-
toms in 120 patients with medically unexplained symp-
toms was not predictive of a DSM-IV-SD diagnosis
(Interian et al., 2004). Importantly, the dual diagnosis of
DSM-IV-SD and FND correlated with poor clinical out-
comes in a 14-year follow-up study of 76 patients with
functional limb weakness (Gelauff et al., 2019).
Dimensional psychopathology
Eleven studies measured dimensional psychological char-
acteristics using self-report or clinician-rated scales in
DSM-IV-SD samples (Sanyal et al., 1998; Brown et al.,
2005; Ozturk and Sar, 2008; Sertoz et al., 2009; Spitzer
et al., 2009; Landa et al., 2012; Taycan et al., 2014;
Kırpınar et al., 2016; Prerana et al., 2017; Davoodi
et al., 2018, 2019 ). Patients with DSM-IV-SD reported
elevated depression scores compared to HCs in one study
(Taycan et al., 2014). Another study compared DSM-IV-
SD patients to those with MDD, finding more anxiety in
the DSM-IV-SD cohort (Spitzer et al., 2009). The number
of bodily complaints positively correlated with depression
and anxiety scores in an DSM-IV-SD sample (Prerana
et al., 2017). Higher rates of suicide attempts and self-
mutilation were also identified in DSM-IV-SD compared
to HCs (Ozturk and Sar, 2008; Taycan et al., 2014).
Dissociation in DSM-IV-SD has also been characterized
in multiple studies (Brown et al., 2005; Taycan et al.,
2014; Kırpınar et al., 2016). Individuals with DSM-IV-
SD exhibited increased dissociation and more trance-like
states compared to HCs (Taycan et al., 2014), as well as
higher dissociative amnesia rates compared to neurologic-
al controls (i.e. dystonia) (Brown et al., 2005).
Studies have characterized an external locus of control
in DSM-IV-SD compared to HCs (Sanyal et al., 1998).
Increased alexithymia, higher level of mistrust and an un-
met need for interpersonal closeness were also identified
in a mixed DSM-IV somatoform disorder cohort (n¼ 20)
compared to HCs (n¼ 20) (Landa et al., 2012).
Furthermore, worse body image and self-esteem were
identified in a mixed somatoform disorders sample (38%
with DSM-IV-SD) compared to both healthy and medical
controls (patients with breast cancer status-post total
mastectomy) (Sertoz et al., 2009). By contrast, when
compared to patients with MDD, individuals with DSM-
IV-SD exhibited less severe maladaptive schemas
(Davoodi et al., 2018) and use of more adaptive emo-
tional regulation strategies (Davoodi et al., 2019).
Traumatic life events
Three studies investigated childhood trauma burden in
DSM-IV-SD cohorts (Brown et al., 2005; Spitzer et al.,
2008; Taycan et al., 2014). Forty women with DSM-IV-
SD reported a greater number of childhood trauma types
and were more likely to have experienced physical abuse
(20%), emotional abuse (25%) and emotional neglect
(30%) compared to 40 healthy women (Taycan et al.,
2014). In another study, 28 individuals with DSM-IV-SD
reported more childhood sexual (43%) and physical
abuse (54%) compared to 28 patients with MDD (Spitzer
et al., 2008). Furthermore, the severity of sexual and
physical abuse distinguished the DSM-IV-SD group from
the MDD cohort (Spitzer et al., 2008). Similarly, more
severe early-life maltreatment distinguished DSM-IV-SD
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from neurological populations, with one study showing
that 22 DSM-IV-SD patients reported more severe child-
hood physical abuse, increased emotional abuse exposure,
greater number of emotional abuse perpetrators, and a
longer duration of emotional abuse compared to 19 dys-
tonia controls (Brown et al., 2005). Those with DSM-IV-
SD also reported more family conflict during childhood
(Brown et al., 2005). In a qualitative, interview-based
study, several patients with DSM-IV-SD articulated links
between early-life maltreatment, somatic symptoms and
healthcare use (Morse et al., 1997).
Regarding lifetime trauma, 40 women with DSM-IV-SD
reported more traumatic events in adulthood (mean¼ 2.6)
than 40 healthy women (mean¼ 1.2), and a higher num-
ber of adulthood traumatic experiences predicted the
DSM-IV-SD diagnosis (Taycan et al., 2014). Three stud-
ies assessed lifetime trauma in mixed cohorts (Carey
et al., 2003; Landa et al., 2012; Brown et al., 2014).
Twenty individuals in a somatoform disorder cohort
comprised of DSM-IV-SD, somatoform pain and undiffer-
entiated somatoform disorders experienced more lifetime
trauma than 20 HCs, and 76% of the traumatic experi-
ences by the patient group were interpersonal in nature
(e.g. assault, divorce and separation) (Landa et al., 2012).
In primary care, 36 individuals with DSM-IV-SD experi-
enced more traumatic lifetime events than 165 medical
patients without DSM-IV-SD (Carey et al., 2003). In 898
twins discordant for lifetime trauma exposure, adverse
experiences correlated with increased risk of developing
DSM-IV-SD (Brown et al., 2014); this highlights the po-
tential etiological relevance of adversity in DSM-IV-SD.
Pathophysiology
Ten inter-related neuroimaging articles reported resting-
state functional MRI (fMRI) findings in a single cohort
of 25 drug-naive patients with DSM-IV-SD compared to
28 HCs (Su et al., 2014; Song et al., 2015; Su et al.,
2015, 2016; Wang et al., 2016; Wei et al., 2016; Guo
et al., 2017; Li et al., 2018; Ou et al., 2018; Pan et al.,
2019) (see Supplementary Table 2). Among the findings
identified, patients with DSM-IV-SD showed increased
functional connectivity within the right inferior temporal
gyrus compared to HCs (Su et al., 2015). Measuring
local and distant functional connectivity, patients with
DSM-IV-SD exhibited increased short-range functional
connectivity in the right superior frontal gyrus and left
pallidum, and increased long-range functional connectivity
in the left middle frontal gyrus and right inferior tem-
poral gyrus (Guo et al., 2017).
In a single photon emission computed tomography
study performed in 11 DSM-IV-SD patients, the most
common findings were a normal single photon emission
computed tomography image (n¼ 4) and right cerebellum
hypoperfusion (n¼ 4) (Garcia-Campayo et al., 2001).
Another study used magnetic resonance spectroscopy to
measure brain metabolites in patients with DSM-IV-SD,
fibromyalgia and HCs (10 subjects per group). The com-
bined DSM-IV-SD and fibromyalgia cohort showed
increased posterior cingulate glutamate levels, but this did
not remain statistically significant when only comparing
DSM-IV-SD patients and HCs (Fayed et al., 2012).
One electrophysiology study measured attention and
working memory mechanisms in 25 DSM-IV-SD patients
and HCs using auditory-evoked potentials (Garcia
Campayo et al., 2007). Patients with DSM-IV-SD had
greater latency in the time needed to perceive, identify
and classify new information (Garcia Campayo et al.,
2007). In an autonomic study, 10 DSM-IV-SD patients
showed higher baseline electrodermal activity (a marker
of increased sympathetic tone) compared to individuals
with DSM-IV conversion disorder and HCs (Sanyal
et al., 1998). Three articles investigated inflammatory
markers in DSM-IV-SD, although no consistent pattern
emerged across studies (Rief et al., 2001; Hossain et al.,
2007a, b).
Treatment
Three treatment studies were specifically performed in
DSM-IV-SD cohorts (Allen et al., 2001, 2006; Fjorback
et al., 2013). In a small within-group study, 11 individu-
als assigned to 10 weekly outpatient CBT sessions
reported less physical discomfort and improved physical
functioning at the end of treatment (Allen et al., 2001).
In a trial comparing outpatient CBT plus a psychiatric
consultation intervention (CBTþPCI; n¼ 43) to a PCI
alone (n¼ 41), the CBTþPCI treatment arm showed
greater improvement in somatic symptoms and physical
functioning (Allen et al., 2006). Fifty-nine subjects
assigned to eight sessions (plus one follow-up) of mind-
fulness therapy showed improved general health, health
anxiety, physical symptoms, anxiety and depression as
compared to 60 patients receiving PCI (Fjorback et al.,
2013).
In addition, several mixed-cohort treatment studies
included individuals with DSM-IV-SD. In a bodily dis-
tress syndrome cohort (n¼ 120; 45% meeting DSM-IV-
SD criteria), subjects who received nine sessions (over 4
months) of outpatient CBT-based treatment plus PCI
showed greater improvement in physical functioning, bod-
ily pain and vitality than those who received a PCI alone
(Schröder et al., 2012). In an inpatient CBT study com-
paring a mixed-somatoform disorders cohort (n¼ 172,
31% meeting DSM-IV-SD criteria) to a mixed psychiatric
cohort (n¼ 123, primarily mood and anxiety disorders),
both groups comparably improved in physical and mental
health measures (Hiller et al., 2003). In a somatization
syndrome cohort (28% meeting DSM-IV-SD criteria),
107 subjects receiving eight sessions of inpatient CBT
plus symptom management training and 84 subjects who
underwent eight sessions of inpatient CBT plus relaxation
training similarly improved in somatic symptoms, mental
health and life satisfaction (Bleichhardt et al., 2004).
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Additional mixed-cohort studies with DSM-IV-SD making
up <20% of the cohort have shown efficacy for intensive
inpatient treatment (involving CBT) (Rief and Hiller,
2003), CBT-based outpatient treatment (Martin et al.,
2007; Zonneveld et al., 2012; Schröder et al., 2013), out-
patient mindfulness therapy (van Ravesteijn et al., 2013)
and progressive muscle relaxation (Schröder et al., 2013).
Other studies have shown efficacy using antidepressants
(Voon and Lang, 2005), and multidisciplinary treatment
(Schrag et al., 2004). See Supplementary Table 3 for add-
itional treatment trial details in DSM-IV-SD.
Discussion
This systematic review of DSM-IV-SD identified a num-
ber of observations that parallel themes emerging in the
DSM-5 FND literature (Ludwig et al., 2018; Baslet et al.,
2020; Perez et al., 2020). Patients with DSM-IV-SD were
predominantly (although not exclusively) female with
increased medical and psychiatric comorbidities, including
functional somatic disorders (e.g. IBS) and elevated rates
of mood, anxiety, trauma-related and personality disor-
ders. Dimensionally, individuals with DSM-IV-SD
reported increased alexithymia, dissociation, an external
locus of control and health anxiety. Of etiological rele-
vance, patients with DSM-IV-SD reported increased child-
hood and lifetime adverse life experiences, including
higher rates compared to healthy and neuropsychiatric
populations. A large twin study discordant for lifetime
trauma exposure showed positive associations between
adverse life experiences and increased risk for DSM-IV-
SD (Brown et al., 2014). Treatment studies also identified
that skills-based psychotherapy was effective in reducing
somatic symptoms in patients with DSM-IV-SD.
Interestingly, neural mechanisms were particularly under-
studied in DSM-IV-SD, which may relate in part to the
low 1-3% prevalence rates driven in the context of overly
stringent diagnostic criteria.
The above overlapping characteristics between DSM-
IV-SD and FND have relevant clinical and research impli-
cations in FND based on three additional observations:
(i) pain is a common comorbid symptom in FND [includ-
ing particularly high rates in pediatric FND (Kozlowska
et al., 2007)] that can limit treatment engagement and
incur a poor prognosis (Glass et al., 2018); (ii) a subset
of FND patients meet criteria for comorbid DSM-IV-SD
(Interian et al., 2004; Schrag et al., 2004; Marchetti
et al., 2008; Stone et al., 2010b; Epstein et al., 2016);
(iii) comorbid DSM-IV-SD in FND is associated with a
poor prognosis (Gelauff et al., 2019). These interrelated
themes demonstrate the importance of explicitly consider-
ing pain in the assessment, management and research of
patients with FND, and underscore the need to better
identify the co-occurrence of pain in FND populations.
Furthermore, based on neurological examination alone,
the assessment of pain requires a more nuanced approach
that is not as straight forward as a ‘rule-in’ diagnosis of
motor FND based on clinical features such as Hoover
sign or tremor entrainment with high diagnostic specifi-
city (Daum et al., 2014). Given concerns regarding SSD
diagnostic criteria (based in part on its psychological
framework) (van der Feltz-Cornelis et al., 2018; Burton
et al., 2020), there is also evidence of heterogeneity in
the willingness of FND clinical experts to diagnose SSD
in patients with FND (Aybek et al., 2020); an alternative
would be to view pain as a commonly present, yet non-
specific symptom of FND. The concern with the latter
approach is that pragmatically, the presence or absence
of pain has high clinical and research relevance, including
but not limited to that predominant pain symptoms have
been an exclusion criteria for physiotherapy trials in
FND (Nielsen et al., 2017). In a randomized feasibility
study of physiotherapy for motor FND conducted by
Nielsen and colleagues, 27% of the 210 patients screened
were excluded based on predominant pain; notably, 47%
of the 60 enrolled nonetheless reported ‘severe to ex-
treme’ pain ratings (Nielsen et al., 2017). Regarding neur-
al mechanisms, the central pain matrix implicated in
chronic pain disorders overlaps with salience (cingulo-in-
sular) network areas implicated in the pathophysiology of
FND (Denk et al., 2014; Begue et al., 2019), underscor-
ing that pain has neurobiological consequences that need
to be considered in FND pathophysiology research. Thus,
to further advance clinical and research efforts in FND,
there is a critical need to provide a practical approach to
identify patients that also have prominent pain.
As a preliminary proposal that we hope will catalyse
considerable discussion in the field [including amongst
the FND Society (www.fndsociety.org) leadership], we
argue that a revision to the DSM-5 should be considered
to explicitly identify the subset of patients with FND that
also have prominent pain. In Fig. 3, we detail the pro-
posed diagnostic criteria allowing for the diagnosis of
FND ‘with prominent pain’ (a specifier). Here, patients
would meet rule-in criteria for sensorimotor FND and
concurrently endorse pain symptoms for at least 6 months
that are also impairing to social and/or occupational
functioning. In an effort to remain etiologically neutral
while acknowledging the biopsychosocial complexity of
predisposing and perpetuating factors, we suggest an op-
tional secondary specifier of ‘with cognitive-behavioral
(psychological) features’. We propose this optional sec-
ondary specifier for the following reasons: (i) an explor-
ation of psychological factors early in the diagnostic
assessment for patients with physical symptoms can be
challenging for both patients and clinicians alike (and
psychological factors related to pain may not be present
in all patients); (ii) identification of psychological con-
structs either amplifying or perpetuating pain have trans-
latable clinical utility (CBT treatment targets), suggesting
that there is merit in identifying this subgroup; (iii) the
use of ‘rule-in’ psychological criteria as proposed in SSD
and related diagnostic formulations remain debated, with
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a recent European workgroup for functional somatic dis-
orders taking a similar etiologically neutral stance to that
outlined above (Burton et al., 2020).
An additional consideration is whether an individual’s
chronic pain symptoms are driven by another recognized
medical/neurological/functional somatic disorder known
to cause pain (e.g. small fibre neuropathy, fibromyalgia,
severe lumbar stenosis) or is part of the intrinsic disease
processes occurring in FND itself. Here, we recommend
another optional secondary descriptive specifier: ‘with a
contributing comorbidity associated with the somatic
symptom(s) of concern’. If such a condition is present,
this can be recorded. The rationale for this specifier is 2-
fold: (i) encourages an appropriate (not necessarily ex-
haustive) medical workup for the individual’s pain
symptoms; and (ii) makes transparent if an identified
pain-related comorbidity is present, which can have both
treatment and research implications. As a cautionary
note, regardless of whether or not this optional specifier
is used, clinicians should evaluate pain, fatigue and other
somatic symptoms without ‘rule-in’ physical examination
features in patients with FND as they would in other
populations (to prevent premature diagnostic anchoring).
While prospective studies are needed to test the reliability
and utility of this suggested DSM-5 revision, we speculate
that this diagnostic approach will identify the vast major-
ity of patients with FND that are also endorsing promin-
ent pain symptoms.
Operationalizing an FND with prominent pain sub-
group has clear clinical and research advantages. By
Figure 3 Preliminary proposal for a revision to the DSM-5 for FND. We suggest the addition of three new specifiers: ‘with prominent
pain’; ‘with prominent fatigue’ and ‘with prominent mixed somatic symptoms’. Patients must first meet complete criteria for FND (criteria A–D).
In addition, pain, fatigue and/or mixed somatic symptoms should themselves be impairing to social and/or occupational functioning and present
for at least 6 months. The above three specifiers are etiologically neutral, which acknowledges the biopsychosocial heterogeneity present in the
development and maintenance of these somatic symptoms. To provide additional clarification, we also propose two optional secondary
specifiers: (i) with symptom-related cognitive-behavioural (psychological) features; and (ii) with a contributing comorbidity associated with the
somatic symptom(s) of concern. The former optional specifier allows the identification of individuals displaying psychological constructs either
amplifying or perpetuating pain that can have clinical utility (e.g. CBT treatment targets). The latter optional specifier encourages an appropriate
(not necessarily exhaustive) medical workup for the identified somatic symptoms, as well as aids the characterization of relevant medical and
neurological comorbidities (including functional somatic disorders) that has been a shortcoming of FND research to date. If a relevant
comorbidity is present, this should be noted when using this optional specifier. Regardless of whether or not this latter optional specifier is used,
clinicians should be mindful to evaluate pain, fatigue and other somatic symptoms without ‘rule-in’ physical examination features in FND patients
as they would in other populations (to prevent premature diagnostic anchoring).
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aiding the identification of this important (and likely
prevalent) FND subgroup, this approach allows clinicians
to consider guiding individuals towards interdisciplinary
mind-body pain programmes that may be potentially
more suitable for initial management in comparison to
emerging motor FND care models (Jimenez et al., 2019).
It also allows for the prioritization of treatment targets
using a stepwise treatment approach in which a patient’s
most prominent physical symptoms are addressed first. In
our opinion, this could optimize the likelihood of success
with physiotherapy. With an improved ability to oper-
ationalize inclusion criteria, our proposal will also cata-
lyse clinical trial research in this potentially more
treatment refractory and costly population. Furthermore,
with the boom in using brain imaging approaches to elu-
cidate the neurocircuitry of FND, and to identify prog-
nostic biomarkers, there is growing need to more
precisely characterize patients that may help explain the
high-degree of variability found in FND studies to date
(Begue et al., 2019).
A related question not yet addressed is how to also
contextualize other prominent physical symptoms in
patients with FND, most notably but not limited to fa-
tigue (Aybek et al., 2020; Gelauff et al., 2020). Like
pain, fatigue is a common symptom in FND that is also
linked to reduced quality of life and reduced treatment
engagement (Vechetová et al., 2018). We suggest that
the same approach taken for pain can also be used to
categorize FND patients with prominent fatigue symp-
toms. This would include using the specifier ‘with prom-
inent fatigue’ for those individuals that endorse fatigue
(>6 months) is limiting their occupational and/or social
functioning. Optional secondary specifiers can denote the
presence or absence of cognitive-behavioural (psycho-
logical) features and the co-occurrence with a contribu-
ting comorbidity known to be associated with fatigue
(e.g. multiple sclerosis, chronic fatigue syndrome). Lastly,
for patients with prominent pain and fatigue, or those
exhibiting a combination of two or more non-sensori-
motor symptoms (e.g. widespread body pain and gastro-
intestinal distress), the diagnostic specifier FND ‘with
prominent mixed somatic symptoms’ can be recorded
(see Fig. 3).
Our systematic review and proposed revised DSM-5
diagnostic criteria for FND have several limitations.
Alternatives approaches such as systematically reviewing
the frequency and relevance of pain, fatigue and other
somatic symptoms in FND more broadly were not per-
formed. Such efforts in the future could further inform
the preliminary DSM-5 revisions proposed here (e.g. 6-
month duration was chosen to be consistent with the
symptom duration requirement for SSD, however, other
durations could be considered). It is also important to
note that many of the observations identified in DSM-IV-
SD, such as increased rates of mood and anxiety disor-
ders, alexithymia, dissociation and adverse life events, are
non-specific features found in a range of other
neuropsychiatric disorders. However, our proposed DSM-
5 FND diagnostic criteria revisions will help catalyse new
research in FND with prominent pain compared to a
range of healthy, medical and neuropsychiatric popula-
tions, which will allow for rigorous investigations of the
relevance and specificity of clinical and neurobiological
associations in this subgroup. In addition, we want to ex-
plicitly note that we are not advocating for a return of
the term ‘SD’, which is fraught with limitations including
a dualistic mind-brain framing and an arbitrary selection
of symptom clusters—must precarious of which is the
sexual symptoms cluster. Another question is the poten-
tial benefit, or lack thereof, of revising the diagnostic cri-
teria for FND within the DSM-5 framework. While we
recognize that psychological factors may not universally
play important predisposing and/or perpetuating roles in
all patients, for many patients cognitive-behavioural (psy-
chological) factors are relevant—particularly for develop-
ing patient-centred treatment plans. As such, it is
important to continue to actively engage psychiatrists,
psychologists and allied mental health professionals as
equal partners alongside neurologists and allied rehabili-
tation specialists in FND-related clinical and research
activities. It will be important, however, for the FND
field to achieve consensus across neurologic and psychi-
atric perspectives, and we hope our etiologically neutral
specifier ‘with prominent pain’ assists in these efforts. We
also welcome our proposal being considered in future
diagnostic criteria considerations by the FND Society.
Lastly, we acknowledge that this article does not address
the question of how to contextualize patients without
sensorimotor FND that experience other distressing phys-
ical symptoms (with normal neurological examinations
and negative medical evaluations). While there are a
range of potential diagnostic classification systems being
actively debated (each with their own strengths and
weaknesses) (Burton et al., 2020), it will be important to
bring together leaders (and patients) across the FND and
functional somatic disorder fields to obtain consensus
across the various stakeholders.
In conclusion, the intersection of FND with other
prominent somatic symptoms, most notably pain, is clin-
ically and prognostically relevant. The changes made
from DSM-IV to DSM-5 eliminated DSM-IV-SD that
encompassed individuals with functional neurological
symptoms and other prominent somatic symptoms. We
propose a preliminary revision to the DSM-5 diagnostic
criteria for FND that adds an etiologically neutral speci-
fier noting the presence of other prominent non-sensori-
motor physical symptoms. While prospective research
studies are needed to validate our proposal, we hope that
this article catalyses discussion on how to optimally con-
textualize pain, fatigue and other physical symptoms in
patients with FND across diagnostic, treatment and
pathophysiology studies.
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